Vesicular Ganglioside GM1 From Breast Tumor Cells Stimulated Epithelial-to-Mesenchymal Transition of Recipient MCF-10A Cells

Ma, Qilong; Zhuo, Dinghao; Guan, Feng; Li, Xiang; Yang, Xiaomin; Tan, Zengqi

doi:10.3389/fonc.2022.837930

Cited by 2 publications

(1 citation statement)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequent investigation revealed that these GM1-enriched EVs from cancer cells transferred their ganglioside components to recipient cells, promoting epithelial-mesenchymal transition (EMT) properties. This further upregulated mesenchymal-related genes such as vimentin and N-cadherins while downregulating the expression of E-cadherin, providing further insight into the molecular mechanism of EMT induction mediated by these GM1-enriched EVs in normal recipient cells ( Ma et al, 2022 ). This suggests a novel and crucial regulatory role of EV associated gangliosides that orchestrates the cellular communication in different pathophysiological circumstances.…”

Section: Effect On Invasion and Migrationmentioning

confidence: 96%

Multi-dimensional role of gangliosides in modulating cancer hallmarks and their prospects in targeted cancer therapy

Sarkar,

Banerjee,

Biswas

2023

Front. Pharmacol.

View full text Add to dashboard Cite

Gangliosides are glycosphingolipids with prevalence in nervous tissue and their involvement in certain neuronal diseases have been widely known. Interestingly, many recent studies highlighted their importance in the development and progression of various cancers through orchestration of multiple attributes of tumorigenesis, i.e., promoting migration, invasion, escaping the host immune system, and influencing other cancer hallmarks. Therefore, the multidimensional role of gangliosides in different cancers has established them as potential cancer targets. However, the tremendous structural complexity and functional heterogeneity are the major challenges in ganglioside research. Moreover, despite numerous immunotherapeutic attempts to target different gangliosides, it has failed to yield consistent results in clinical trials owing to their poor immunogenicity, a broad range of cross-reactivity, severe side effects, lack of uniform expression as well as heterogeneity. The recent identification of selective O-acetylated ganglioside expression in cancer tissues, but not in normal tissues, has strengthened their potential as a better and specific target for treating cancer patients. It was further supported by reduced cross-reactivity and side effects in clinical trials, although poor immunogenicity remains a major concern. Therefore, in addition to characterization and identification of the biological importance of O-acetylated gangliosides, their specific and efficient targeting in cancer through engineered antibodies is an emerging area of glycobiology research. This review highlights the modulatory effect of select gangliosides on different hallmarks of cancer and presents the overall development of ganglioside targeted immunotherapies along with recent progress. Here, we have also discussed its potential for future modifications aimed towards improvement in ganglioside-based cancer therapies.

show abstract

Section: Effect On Invasion and Migrationmentioning

confidence: 96%

Multi-dimensional role of gangliosides in modulating cancer hallmarks and their prospects in targeted cancer therapy

Sarkar,

Banerjee,

Biswas

2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

The cancer glycocode as a family of diagnostic biomarkers, exemplified by tumor-associated gangliosides

Nejatie,

Yee,

Jeter

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

One unexploited family of cancer biomarkers comprise glycoproteins, carbohydrates, and glycolipids (the Tumor Glycocode).A class of glycolipid cancer biomarkers, the tumor-marker gangliosides (TMGs) are presented here as potential diagnostics for detecting cancer, especially at early stages, as the biological function of TMGs makes them etiological. We propose that a quantitative matrix of the Cancer Biomarker Glycocode and artificial intelligence-driven algorithms will expand the menu of validated cancer biomarkers as a step to resolve some of the challenges in cancer diagnosis, and yield a combination that can identify a specific cancer, in a tissue-agnostic manner especially at early stages, to enable early intervention. Diagnosis is critical to reducing cancer mortality but many cancers lack efficient and effective diagnostic tests, especially for early stage disease. Ideal diagnostic biomarkers are etiological, samples are preferably obtained via non-invasive methods (e.g. liquid biopsy of blood or urine), and are quantitated using assays that yield high diagnostic sensitivity and specificity for efficient diagnosis, prognosis, or predicting response to therapy. Validated biomarkers with these features are rare. While the advent of proteomics and genomics has led to the identification of a multitude of proteins and nucleic acid sequences as cancer biomarkers, relatively few have been approved for clinical use. The use of multiplex arrays and artificial intelligence-driven algorithms offer the option of combining data of known biomarkers; however, for most, the sensitivity and the specificity are below acceptable criteria, and clinical validation has proven difficult. One strategic solution to this problem is to expand the biomarker families beyond those currently exploited. One unexploited family of cancer biomarkers comprise glycoproteins, carbohydrates, and glycolipids (the Tumor Glycocode). Here, we focus on a family of glycolipid cancer biomarkers, the tumor-marker gangliosides (TMGs). We discuss the diagnostic potential of TMGs for detecting cancer, especially at early stages. We include prior studies from the literature to summarize findings for ganglioside quantification, expression, detection, and biological function and its role in various cancers. We highlight the examples of TMGs exhibiting ideal properties of cancer diagnostic biomarkers, and the application of GD2 and GD3 for diagnosis of early stage cancers with high sensitivity and specificity. We propose that a quantitative matrix of the Cancer Biomarker Glycocode and artificial intelligence-driven algorithms will expand the menu of validated cancer biomarkers as a step to resolve some of the challenges in cancer diagnosis, and yield a combination that can identify a specific cancer, in a tissue-agnostic manner especially at early stages, to enable early intervention.

show abstract

Vesicular Ganglioside GM1 From Breast Tumor Cells Stimulated Epithelial-to-Mesenchymal Transition of Recipient MCF-10A Cells

Cited by 2 publications

References 68 publications

Multi-dimensional role of gangliosides in modulating cancer hallmarks and their prospects in targeted cancer therapy

Multi-dimensional role of gangliosides in modulating cancer hallmarks and their prospects in targeted cancer therapy

The cancer glycocode as a family of diagnostic biomarkers, exemplified by tumor-associated gangliosides

Contact Info

Product

Resources

About